Jade Biosciences Inc (JBIO)
Jade Biosciences, Inc. is a NASDAQ-listed biotechnology company focused on developing therapies for inflammation and immunology indications in patients with autoimmune diseases. Its lead program, JADE101, is a monoclonal antibody designed to block the A PRoliferation Inducing Ligand protein and is currently in phase 1 clinical testing. The company also has two earlier-stage candidates, JADE201 and JADE-003, which remain in preclinical development. Jade Biosciences has a collaboration agreement with Paragon Therapeutics, Inc. The company is based in Waltham, Massachusetts.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-JBIO
|
$14.52
|
-29.3% Downside
|
Overvalued
|
$48.50
|
136.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-12.8x
|
4.1x
|
—
|
1.168 B
|
908.2 M
|
0.1%
|
73.9%
|
29.3
|
—
|
105.4%
|
